INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $100.00K, a 0.00% change year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $100.00K, a 0.00% change year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $100.00K, a 0.00% change year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $200.00K, a 50.00% decline from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $400.00K, a 50.00% decline from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $800.00K, a 20.00% decline from fiscal 2022.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-13 | $100.00K 10-Q · filed 2026-08-13 | $300.00K derived: sum of 3 quarters · filed 2026-08-13 | $300.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-14 | $200.00K derived: sum of 2 quarters · filed 2026-05-14 | $200.00K derived: sum of 3 quarters · filed 2026-05-14 | $300.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $100.00K derived: sum of 2 quarters · filed 2026-03-05 | $200.00K derived: sum of 3 quarters · filed 2026-08-13 | $200.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $100.00K derived: sum of 2 quarters · filed 2026-08-13 | $100.00K 10-Q · filed 2025-11-06 | $300.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-13 | $100.00K 10-Q · filed 2026-08-13 | $300.00K derived: sum of 3 quarters · filed 2026-08-13 | $400.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-14 | $200.00K derived: sum of 2 quarters · filed 2026-05-14 | $300.00K derived: sum of 3 quarters · filed 2026-05-14 | $500.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $200.00K derived: sum of 2 quarters · filed 2026-03-05 | $400.00K derived: sum of 3 quarters · filed 2026-03-05 | $400.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-06 | $300.00K derived: sum of 2 quarters · filed 2025-11-06 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $200.00K 10-Q · filed 2025-08-14 | $200.00K 10-Q · filed 2025-08-14 | $500.00K derived: sum of 3 quarters · filed 2025-08-14 | $600.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $300.00K derived: sum of 2 quarters · filed 2025-05-15 | $400.00K derived: sum of 3 quarters · filed 2025-05-15 | $500.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $400.00K derived: sum of 2 quarters · filed 2025-03-20 | $500.00K derived: sum of 3 quarters · filed 2025-03-20 | $800.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-14 | $200.00K derived: sum of 2 quarters · filed 2024-11-14 | $500.00K 10-Q · filed 2024-11-14 | $500.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-14 | $400.00K 10-Q · filed 2024-08-14 | $400.00K derived: sum of 3 quarters · filed 2024-08-14 | $800.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-09 | $300.00K derived: sum of 2 quarters · filed 2024-05-09 | $700.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $400.00K derived: sum of 2 quarters · filed 2024-03-28 | $700.00K derived: sum of 3 quarters · filed 2024-03-28 | $1.00M 10-K · filed 2024-03-28 |
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-09 | $700.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.00M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-10 | $600.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 8-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |